Benjamin K. Gibbs

University of Wisconsin–Madison — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index340citations26works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(11), Renal cell carcinoma treatment(6), Renal and related cancers(4), Cancer Cells and Metastasis(3), Microtubule and mitosis dynamics(3)

Publications26 total

Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma
Pigment Cell & Melanoma Research·2025· 2 citedOpen Access
Tracking Small Extracellular Vesicles Using a Minimally Invasive PicoGreen Labeling Strategy
ACS Applied Bio Materials·2024· 5 citedOpen Access
CGE24-095: Microfluidic Characterization and Analysis of Circulating Tumor Cells from Patients with Metastatic Melanoma
Journal of the National Comprehensive Cancer Network·2024
JoVE Video Dataset
2023
Rapid <em>In Vitro</em> Cytotoxicity Evaluation of Jurkat Expressing Chimeric Antigen Receptor using Fluorescent Imaging
Journal of Visualized Experiments·2023· 3 citedOpen Access
Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma
Cancers·2023· 4 citedOpen Access
Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma
Preprints.org·2023· 1 citedOpen Access
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma
Journal of Experimental & Clinical Cancer Research·2023· 16 citedOpen Access
Abstract 5334: Targeting the KIF15-TPX2 PPI to overcome KIF11 inhibitor resistance in epithelial ovarian cancer
Cancer Research·2023· 1 cited
Data from Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation
2023Open Access
Supplementary Methods, Supplementary Figures S1, S2, Supplementary Tables S1-S3 from Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation
2023Open Access
Supplementary Methods, Supplementary Figures S1, S2, Supplementary Tables S1-S3 from Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation
2023Open Access
Data from Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation
2023Open Access
Additional file 2 of High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma
Figshare·2023Open Access
Hypoxic preconditioning protects against ischemic kidney injury through the IDO1/kynurenine pathway
Cell Reports·2021· 44 citedOpen Access
Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma
Molecular Oncology·2021· 21 citedOpen Access
High-throughput small molecule screens reveal therapeutic opportunities against TFE3-fusion renal cell carcinoma
European Journal of Cancer·2020
Abstract 4585: Development of multi-marker capture and analysis of circulating tumor cells in renal cell carcinoma
Cancer Research·2018
Targeting loss of the Hippo signaling pathway in <i>NF2</i>-deficient papillary kidney cancers
Oncotarget·2018· 57 citedOpen Access
Detecting the Potential Pharmacological Synergy of Drug Combination by Viability Assays In Vitro
Methods in molecular biology·2017· 5 cited
page 1 of 2Next →

Frequent Co-authors

Joshua M. Lang(11), Jamie M. Sperger(8), Carole Sourbier(7), Erika Héninger(7), David J. Beebe(7), Lindsay N. Strotman(6), Benjamin P. Casavant(6), Stephanie M. Thiede(6), Andrew K. Godwin(6), Allison W. Welsh(5), Zachery Chalmers(5), Sacha Horn(5), Jacob Tokar(5), David J. Guckenberger(5), Lakeesha Carmichael(5), Scott M. Dehm(5), Philip J. Stephens(5), Christopher J. Ricketts(5), Darmood Wei(5), W. Marston Linehan(4)